Minireviews
Copyright ©The Author(s) 2022.
World J Clin Oncol. Apr 24, 2022; 13(4): 267-275
Published online Apr 24, 2022. doi: 10.5306/wjco.v13.i4.267
Table 2 Recently published practice changing phase 3 studies in Malignant Pleural Mesothelioma
Clinical trial (Phase)
Population
Treatment arms
mOS
mPFS
AEs G3
CheckMate 743 (Phase III)[35]Untreated MPMNivolumab 3 mg/kg every 2 wk + ipilimumab 1 mg/kg every 6 wk18.1 moHR: 0.74, P = 0.0026.8 moHR: 1.0030%
Cisplatin + pemetrexed14.1 mo7.6 mo32%
CONFIRM (Phase III)[29]Relapsed MPMNivolumab 3 mg/kg every 2 wk9.2 mo HR: 0.72, P = 0.0023 mo HR: 0.61; P < 0.00119%
Placebo6.6 mo1.8 mo6.3%